DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing

DBV Technologies announced it has completed extensive discussions with the FDA regarding its Biologics License Application (BLA) for the VIASKIN® Peanut Patch in children aged 4-7 years. The FDA did not request additional data, but DBV will incorporate feedback on data organization and formatting before submitting the BLA in Q3 2026.